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Obesity-related inflammation of metabolic tissues,
including visceral adipose tissue (VAT) and liver,
are key factors in the development of insulin resis-
tance (IR), though many of the contributing mech-
anisms remain unclear. We show that nucleic-
acid-targeting pathways downstream of extracel-
lular trap (ET) formation, unmethylated CpG DNA,
or ribonucleic acids drive inflammation in IR.
High-fat diet (HFD)-fed mice show increased
release of ETs in VAT, decreased systemic clear-
ance of ETs, and increased autoantibodies against
conserved nuclear antigens. In HFD-fed mice, this
excess of nucleic acids and related protein anti-
gens worsens metabolic parameters through a
number of mechanisms, including activation of
VAT macrophages and expansion of plasmacytoid
dendritic cells (pDCs) in the liver. Consistently,
HFD-fed mice lacking critical responders of nu-
cleic acid pathways, Toll-like receptors (TLR)7
and TLR9, show reduced metabolic inflammation
and improved glucose homeostasis. Treatment of
HFD-fed mice with inhibitors of ET formation or a
TLR7/9 antagonist improves metabolic disease.
These findings reveal a pathogenic role for nucleic
acid targeting as a driver of metabolic inflamma-
tion in IR.This is an open access article under the CC BY-NINTRODUCTION
Insulin resistance (IR) precedes type 2 diabetes and is a key
feature of obesity-related metabolic syndrome. Multiple factors
contribute to insulin sensitivity, but inflammation of visceral adi-
pose tissue (VAT) and liver, leading to chronic release of pro-in-
flammatory cytokines, is a major contributor (Osborn and Olef-
sky, 2012). Within VAT, macrophages, T cells, B cells, innate
lymphoid cells, eosinophils, and neutrophils take part in this pro-
cess (Mathis, 2013). Neutrophils promote IR in high-fat diet
(HFD)-fed mice through secretion of elastase (Talukdar et al.,
2012) and myeloperoxidase (Wang et al., 2014a). In addition to
their traditional antimicrobial mechanisms, neutrophils can
release extracellular traps (ETs), composed of nucleic acids
and antimicrobials, to entrap pathogens and limit infection
(Brinkmann et al., 2004). Macrophages also extrude ET-like
structures (Chow et al., 2010; Liu et al., 2014; Webster et al.,
2010). Recently, these macrophage ET-like structures have
been identified within crown-like structures (CLSs) in mammary
gland subcutaneous adipose tissue (SAT) of mice (Mohanan
et al., 2013), though this process needs further characterization.
Aberrant production and reduced clearance of ETs can lead to
accumulation of immunogenic self-antigens and promotion of
autoimmune diseases, such as systemic lupus erythematosus
(SLE) (Garcia-Romo et al., 2011; Hakkim et al., 2010) and type
1 diabetes (Diana et al., 2013; Wang et al., 2014b). Remarkably,
SLE is highly linked to metabolic syndrome (Demir et al., 2016;
Parker et al., 2015), with enhanced development of IR (Parker
and Bruce, 2010). In SLE, aberrant antibody targeting of nucleic
acids potentiates inflammation through Toll-like receptor (TLR)7Cell Reports 16, 717–730, July 19, 2016 ª 2016 The Author(s). 717
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Aberrant Production of ETs during HFD Feeding
(A) Absolute number of CD11b+Ly6g+ neutrophils and F480+ macrophages in the visceral adipose tissue (VAT) of mice fed either a normal control diet (NCD) or a
high-fat diet (HFD) for 2, 8, and 15 weeks is shown (n = 10 mice, three experiments, *p < 0.05).
(B) Release of extracellular traps (ETs) by BMneutrophils harvested frommice fed anNCD or HFD for 2, 8, and 15weeks, left non-stimulated (NS) or activatedwith
phorbol 12-myristate, 13-acetate (PMA) for 6 hr. At the 15-week time point, cells also were stimulated with reactive oxygen species (ROS), E. coli lipopoly-
saccharide (LPS), heat-killed Listeria monocytogenes (HKLM), and single-stranded RNA oligonucleotides (ssRNA).
(C) Release of ETs by BMmonocytes harvested from mice fed an NCD or HFD for 2, 8, and 15 weeks, left NS or activated with LPS for 6 hr. At the 15-week time
point, cells also were stimulated with PMA, ROS, interferon-g (IFNg), or elastase (ELA).
(B andC) ETs were quantified with SytoxGreen staining and fluorescencemeasurements were taken every 30min. Data represent the area under the curve (AUC)
calculated from plotted fluorescent measurements over time (n = 6 mice per group, *p < 0.05).
(legend continued on next page)
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and/or TLR9 activation in macrophages (in mice), B cells, and
plasmacytoid dendritic cells (pDCs) (Liu and Davidson, 2012).
Neutrophil ETs (NETs) also have been shown to increase the pro-
duction of proinflammatory cytokines by CD4+ and CD8+ T cells
(Tillack et al., 2012) and act onmonocytes in lupus to activate the
NLRP3 inflammasome (Kahlenberg et al., 2013). Notably, a
recent study has shown that types 1 and 2 diabetes predispose
neutrophils to release increased NETs, which delays wound
healing in humans and mice (Wong et al., 2015). However, a
pathophysiological role for ETs in promoting glucose intolerance
during obesity is unknown.
In addition to endogenous sources of nucleic acids, TLR9 li-
gands from exogenous sources, including unmethylated CpG,
may contribute to inflammation in obesity. Indeed, obesity is
associated with altered composition of the gut microbiota, and
this dysbiosis can influence IR (Cani et al., 2008). In fact, some
of the systemic inflammation associated with IR is thought to
result from increased serum levels of leaked gut bacterial prod-
ucts, such as lipopolysaccharide (LPS), and unmethylated CpG
DNA, which may exert effects systemically or locally in VAT or
liver (Henao-Mejia et al., 2012).
Here we show that alterations in nucleic acid-targeting path-
ways occur in HFD-induced obesity and impact the develop-
ment of metabolic disease. Downstream immunological re-
sponses to nucleic acids are important drivers of inflammation
in obesity-related IR, and they represent a source of antigenic
targets and potential therapies in IR.
RESULTS
HFD Promotes Increased ET Formation
Because ET formation has been implicated in the pathogenesis
of several inflammatory diseases, we hypothesized ET release
would be augmented in response to HFD feeding. First, we
determined the presence of ET-releasing immune cells, such
as neutrophils and macrophages within VAT, during the course
of HFD feeding. Compared with normal control diet (NCD)-fed
mice, the number of VAT neutrophils substantially increased af-
ter 8 and 15 weeks, while VAT macrophage numbers increased
following 2, 8, and 15 weeks of HFD feeding (Figure 1A).
To assess the effects of HFDon ET production froma systemic
hematolymphoid source, we analyzed ET formation by bone
marrow (BM) neutrophils and monocytes using the extracellular
DNA dye Sytox and by immunostaining of citrullinated histones.
Histone citrullination is required for chromatin decondensation
during ETosis, and certain patterns of histone citrullination are
considered specific markers of ET formation (Wang et al.,(D) Percentage of ET-releasing, granulocyte receptor (Gr)-1+ stromal vascular
(triplicates, n = 10 mice per group, *p < 0.05).
(E) Representative immunofluorescence images showing DNA (blue), ELA (green
4-hr incubation with LPS (scale bar, 40 mm). Yellow arrows indicate ETs.
(F) Quantification of H4Cit3+ cells (left) and ET-releasingmonocytes/macrophages
*p < 0.05).
(G) Scanning electron microscopy (SEM) images show BM and VAT macrophag
(H) SEM image shows immunogold-labeled H4Cit3 in ETs released by an LPS-s
(I) Production of IL-1b (left) and TNF-a (right) by LPS-primed VAT macrophages fr
three experiments, *p < 0.05). Error bars show mean ± SEM.
See also Figures S1, S2, and S3 and Data S1.2009). Compared with NCD-fed controls, BM neutrophils from
mice fed a HFD for 8 and 15 weeks released increased amounts
of NETs when stimulated with phorbol 12-myristate 13-acetate
(PMA) and reactive oxygen species (ROS), but not upon stimula-
tion with several TLR agonists (Figure 1B). HFD feeding also
increased the release of BM monocyte/macrophage ET-like
structures (METs) at 8 and 15 weeks of dietary treatment, but
only in LPS-stimulated cells (Figure 1C), suggesting fundamental
differences between the stimulation process leading to NET and
MET formation. We confirmed that our fluorescence-based
assay was specific for extracellular DNA, since the addition of
DNase-1 abolished the fluorescence signal (Figure S1A) and
mass spectrometry (MS) analysis showed that the proteins asso-
ciated with these NETs and METs included histones and several
antimicrobials (Data S1), as previously reported (Urban et al.,
2009).
We next assessed whether diet-induced obesity (DIO) re-
sults in increased release of ETs in active metabolic tissues,
such as inflamed VAT. Stromal vascular cells (SVCs) harvested
from VAT of NCD- and HFD-fed mice were stained for histone
3, a component of ETs. Immunostaining for histone 3 showed
intracytoplasmic and extracellular translocation of histone pro-
tein characteristic of ETosis (Figure S1B). The percentage of
Gr-1+ SVCs, which include primarily neutrophils and some
macrophages, releasing ETs was dramatically increased in
HFD-fed mice compared with NCD-fed controls in non-stimu-
lated and stimulated states (Figure 1D). To confirm that
increased histone 3 in VAT of HFD-fed mice is indicative of
ET formation, adipose tissue sections from NCD- and HFD-
fed mice were stained for histone 4-citrulline 3 (H4-Cit3).
Compared with NCD controls, VAT from HFD-fed mice
showed increased H4-Cit3 in the nucleus and cytoplasm of
neutrophils and macrophages and in CLS near adipocytes
(Figure S2A). VAT of obese patients with a previous diagnosis
of type 2 diabetes also showed positive staining of H4-Cit3,
suggesting that ETs may be present during obesity-induced
VAT inflammation in humans, although this finding needs
future characterization (Figure S2A).
Because proinflammatory macrophages play a pivotal role
in chronic low-grade inflammation during obesity and are
far more numerous in VAT compared with neutrophils, we
next investigated whether HFD alters the production of ETs
by monocyte/macrophages in VAT. Monocyte/macrophages
from BM and VAT of HFD-fed mice were stimulated with LPS
and immunostained for H4-Cit3 and elastase (Figure 1E; Fig-
ure S2B). Compared with BM cells, VAT macrophages had
increased percentages of both H4-Cit3+ and ET-releasing cellscells (SVCs) harvested from VAT of either NCD- or HFD- fed mice is shown
), and H4Cit3 (red) in BM monocytes and VAT macrophages, left NS or after a
(right) in immunofluorescence images is shown (n = 10mice, two experiments,
es left NS or after incubation with LPS for 4 hr.
timulated macrophage from the VAT of HFD-fed mice.
om HFD-fed mice following exposure to purified NETs and METs (n = 10 mice,
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Figure 2. HFD-Induced Obesity Promotes
Defective ET Degradation and Elevated
Autoantibody Titers against Nucleic Acids
and Related Antigens
(A–C) ET degradation by serum alone (A), sup-
plemented with DNase (B), or MNase (C) collected
from mice fed either an NCD or HFD for 15 weeks
is shown (n = 6, *p < 0.05).
(D) Heatmap of mean fluorescence intensity (MFI)
showing IgM antibody levels against self-antigens
in serum from NCD- and HFD-fed mice (n = 9).
Antibody levels are in shades of yellow with high-
est titers as bright yellow (bright yellow represents
anMFIR 10,000). The heatmap displays antibody
reactivity significantly associated with HFD versus
NCD feeding, as assessed by the SAM algorithm
(q < 0.001) and grouped by Euclidean distance
hierarchical clustering. RAG-deficient mice were
used as negative controls (far left lanes).
(E) Relative plasma levels of anti-nuclear anti-
bodies (ANAs) in normal weight (n = 15) and
overweight/obese (n = 9) patients (*p < 0.05). Data
represent absorbance a.u.
(F) Plasma concentrations of anti-dsDNA (left) and
anti-histone (right) IgG determined by ELISA in
mice fed an NCD or HFD for 15 weeks are shown
(n = 7, *p < 0.05).
(G) ELISPOT analysis of VAT SVCs enriched for B
cells from mice fed an NCD or HFD for 15 weeks
seeded onto plates coated with histone (left) and
dsDNA (right, n = 14 mice each, two experiments,
*p < 0.05). Error bars show mean ± SEM.
See also Figure S4 and Table S1.(Figure 1F). Notably, VAT macrophages showed increased H4-
Cit3 staining and MET release, even in the absence of stimuli
(Figure 1F), suggesting an activated phenotype in vivo. Further-
more, scanning electron microscopy (SEM) images of BM
monocytes and VATmacrophages showed the typical extracel-
lular fibers (Figure 1G; Figure S3), corroborating their ability to
form ET-like structures. In addition, immunogold labeling of
ET-releasing VAT macrophages for SEM showed H4-Cit3
concentrated in these structures (Figure 1H), confirming the
formation of METs.
We next investigated whether NETs and METs can directly
activate VAT macrophages, promoting the release of inflamma-
tory cytokines IL-1b and TNF-a. VAT macrophages from HFD-
fed mice were exposed for 2 hr to ET-associated components
produced by BM neutrophils and macrophages (Urban et al.,
2009). Both NET- and MET-associated components increased720 Cell Reports 16, 717–730, July 19, 2016the amounts of the IL-1b and TNF-a in
the supernatants of VAT macrophages
(Figure 1I), suggesting a direct link be-
tween excessive ET release and VAT
macrophage activation during DIO.
Collectively, these results indicate that
HFD-derived VAT macrophages have
increased ability to release ETs, com-
pared with their BM precursors, and
that ETs have potential to fuel local im-mune activation and cytokine production in metabolic tissue,
revealing a mechanism of inflammation in VAT during obesity.
Defective ET Degradation and Autoantibody Production
against Nucleic Acid-Related Antigens Are Hallmarks
of DIO
Since ETs are increased systemically and locally in metabolic tis-
sues during HFD feeding, and ineffective systemic clearance of
ETs promotes the production of antibodies against self-antigens
(Hakkim et al., 2010), we next sought to investigate whether sys-
temic ET clearance and autoantibody production are altered in
HFD-fed mice. After ETs were induced ex vivo, they were incu-
bated with serum from mice fed either an NCD or HFD, and ET
degradation was determined. Compared with serum from NCD
controls, serum from HFD mice showed reduced capacity to
degrade ETs (Figure 2A). To determine whether this ineffective
ET degradation was due to low serum DNase activity, exoge-
nous DNase was added to the reactions. DNase spiking
increased ET clearance in NCD serum to levels close to 100%;
however, it only marginally improved clearance by HFD serum
(Figure 2B). Indeed, treatment of HFD-fed mice with DNase
had no effect on glucose tolerance (Figure S4). Therefore,
reduced ET degradation in HFD mice is not caused by low
DNase activity, but it is likely due to the presence of either DNase
inhibitors or the physical protection of ETs against DNase. To
further clarify these possibilities, we spiked serum from NCD
and HFD mice with the non-specific nuclease micrococcal
nuclease (MNase). Spiking HFD serum with MNase did not
restore ET degradation relative to NCD serum (Figure 2C), sug-
gesting protection of ETs from nuclease activity.
We next proposed that the aberrant production and defective
clearance of ETs would elicit increased production of autoanti-
bodies against components of ETs. Using a custom-made array
(Price et al., 2013), we screened serum from HFD-fed mice for
>200 autoantibodies, and we detected a group of auto-antigens
that differed between NCD and HFDmice, including the U1 small
nuclear ribonucleoprotein (RNP) 86; the histones H1, H2A, H2B,
and H3; and double-stranded DNA (dsDNA) (Figure 2D).
Remarkably, overlapping findings also are seen in a cohort of
normal weight versus overweight/obese human subjects (clinical
parameters summarized in Table S1). Specifically, the levels of
anti-nuclear antibodies (ANAs), which include autoantibodies
against dsDNA, histones, and RNPs, are increased in the plasma
of overweight or obese humans compared with normal weight
subjects (Figure 2E). In agreement with the array findings, we
validated the plasma levels of anti-dsDNA and anti-histone
IgGs with ELISA, and these autoantibodies were increased in
HFD-fed mice (Figure 2F). To assess whether this adaptive im-
mune response against nucleic acid-related antigen occurs
both systemically and locally in VAT, total splenocytes and B
cell-enriched VAT-derived SVCs from NCD and HFD mice
were assessed by ELISPOT for B cell production of IgG against
histone and dsDNA. IgG production against dsDNA and histone
2A by splenic and VAT B cells was strikingly augmented in HFD-
fed mice compared with NCD-fed controls (Figure 2G). These
data suggest that increased autoantibody production against
nucleic acid-related antigens occurs systemically in hematolym-
phoid organs and locally in VAT, consistent with a role for target-
ing of nucleic acid-related antigen during HFD feeding.
Nucleic Acid-Sensing Receptors Regulate Glucose
Homeostasis and Insulin Signaling
We next investigated the roles of the downstream target recep-
tors TLR7 and TLR9 in DIO-related IR. These TLRs often gain ac-
cess to nucleic acids after cell-mediated uptake of antibody-an-
tigen complexes, where they recognize nucleoprotein antigens
such as RNPs (TLR7) (Savarese et al., 2006) and dsDNA (TLR9)
(Martin and Elkon, 2005). First, we asked whether ET-associated
components can be sensed by TLR7 and TLR9 in VAT macro-
phages. Macrophages purified from the VAT of HFD-fed wild-
type (WT), TLR7/, and TLR9/ mice were exposed for 2 hr
to ET-associated components to determine their release of
proinflammatory cytokines. Compared with VAT macrophages
from WT mice, those from TLR7/ and TLR9/ mice showedreduced release of IL-1b and TNF-a (Figure 3A), suggesting
that these nuclear receptors are partly responsible for the activity
of macrophages observed after treatment with ET components.
Therefore, we next determined the effects of genetic deletion
of TLR7 and TLR9 on metabolic parameters in NCD- and HFD-
fedmice. Despite no differences in body weight (BW) (Figure 3B),
HFD TLR7/ and TLR9/ mice showed improved glucose
tolerance tests (GTTs) compared with HFD WT littermate con-
trols (Figure 3C). Furthermore, HFD TLR7/ and TLR9/ mice
had lower fasting insulin (Figure 3D), improvements in insulin
tolerance tests (ITTs) (Figure 3E), and decreased VAT fat pad
weight (Figure 3F) compared with littermate WT mice. HFD
TLR9/, but not TLR7/, mice also showed a decrease in liver
weights (Figure 3G), as well as decreased hepatic steatosis (Fig-
ure S5A). Compared with WT controls, HFD-fed TLR7/ and
TLR9/mice had similar maximal O2 consumption (Figure S5B),
CO2output (Figure S5C), respiratory exchange ratio (Figure S5D),
energy expenditure (Figure S5E), and food intake (Figure S5F).
Acute insulin response studies showed improved adipose insulin
signaling in TLR7/ and TLR9/ mice and enhanced hepatic
insulin signaling in TLR9/ mice, as indicated by insulin-stimu-
lated phosphorylation of Akt (Figure 3H). In addition, the levels of
anti-dsDNA (Figure 3I) and anti-histone (Figure 3J) IgGs were
decreased in HFD TLR7/ and TLR9/ mice, indicating that
these mice are protected from the increased production of auto-
antibodies against components of ETs observed in HFD WT
mice. Compared with their WT controls, NCD-fed TLR7/ and
TLR9/ mice had similar BW, fasting glucose, GTTs, and ITTs
(Figures S5G–S5J). Together these data demonstrate that the
endosomal nucleic acid-sensing receptors TLR7 and TLR9
contribute to glucose intolerance and IR during HFD feeding,
and they provide an additional means by which aberrant nucleic
acid production causes IR in obesity.
Nucleic Acid-Targeting Pathways Contribute to Immune
Cell-Mediated Inflammation in VAT and Liver
Since TLR7 and TLR9 deletion improved metabolic parameters,
we hypothesized that resident immune populations expressing
these receptors in metabolic tissues would be altered upon
HFD feeding in these mice. Both TLR7/ and TLR9/ mice
had fewer CLSs in VAT (Figures 4A and 4B) and total number
of VAT macrophages (Figure 4C). VAT macrophages showed
decreased expression of the immune activation marker CD80
(Figure 4D). Furthermore, TLR7/ mice showed lower percent-
ages of inflammatory M1 and resident M2-polarized macro-
phages, whereas TLR9/ mice had a decrease in the percent-
age of M1 macrophages (Figure 4E).
In addition to macrophages, pDCs selectively express TLR7
and TLR9 and are capable of recognizing autoantibody com-
plexes against nucleic acids. In chronic inflammatory diseases
such as SLE, TLR7 and TLR9 facilitate the recognition of autoan-
tibodies against nucleic acids, leading to activation of pDCs and
secretion of inflammatory cytokines, including type I interferon
(IFN) (Liu and Davidson, 2012). Because the role of pDCs in
obesity-induced inflammation has not been investigated, we first
determined the total number of pDCs in VAT, liver, and spleen of
NCD- and HFD-fed mice. While pDCs were almost undetectable
in the VAT, distinct mPDCA-1+ Siglec-H+ pDC populations wereCell Reports 16, 717–730, July 19, 2016 721
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Figure 3. Genetic Deletion of Nucleic Acid-Sensing Receptors Improves Glucose Homeostasis and Insulin Signaling during HFD Feeding
(A) Production of IL-1b (left) and TNF-a (right) by VATmacrophages fromWT, TLR7/, and TLR9/mice fed an HFD following exposure to purified ETs is shown
(n = 10 mice, three experiments, *p < 0.05).
(B–D) Body weights (BWs, B), GTTs (C), and fasting insulin (D) of TLR7/, TLR9/, and their WT littermate control mice fed an HFD for 15 weeks are shown (n = 6
for TLR7/, n = 9 for TLR9/, n = 6 or 9 for WT mice; *p < 0.05).
(E–G) ITTs (E), gonadal fat pad weights (F), and liver weights (G) of TLR7/, TLR9/, and their WT littermate control mice fed an HFD for 15 weeks are shown
(n = 5, except in E where n = 6 for TLR7/, n = 9 for TLR9/, and n = 6 or 9 for WT mice; *p < 0.05).
(H) Representative western blots (left) and quantification (right) of total and pAkt in liver (n = 7 for TLR7/, n = 4 for TLR9/) and VAT (n = 4), after injection of
0.75 or 1.5 units per kg1 i.p. of insulin in HFD-fed WT, TLR7/, and TLR9/ mice, are shown (*p < 0.05).
(I and J) Plasma concentrations of anti-dsDNA (I) and anti-histone (J) IgG determined by ELISA in TLR7/, TLR9/, and their WT control mice fed an HFD for
15 weeks (n = 5, *p < 0.05). Error bars show mean ± SEM.
See also Figure S5.
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identified in the liver and spleen of HFD and NCD mice, with a
marked increase in the frequency (Figures S4D and S4E) and
numbers (Figure 4F) of pDCs in the liver of HFD-fed mice
compared with NCD controls. Notably, HFD mice also showed
an increase in the frequency of proinflammatory CCR9 pDCs
and a reduction in the frequency of tolerogenic CCR9+ pDCs
(Hadeiba et al., 2008) in the liver (Figure 4G).
We then assessed pDC populations in TLR7/ and TLR9/
mice to examine the possibility that liver pDCs could partly
mediate some of the metabolic effects of these TLRs in DIO.
Compared with HFD WT controls, both HFD TLR7/ and
TLR9/mice had decreased numbers of pDCs in the liver (Fig-
ure 4H), with results being more marked in TLR9/mice. TLR9-
deficient mice also showed a large shift in pDC populations from
the pro-inflammatory CCR9 toward the tolerogenic CCR9+
phenotype (Figure 4I). As activated pDCs produce large amounts
of IFNa, we assessed whether HFD feeding would predispose
pDCs to release increased IFNa. Livers from HFD-fed mice
had no changes in the frequency (Figure S4F) but a substantial
increase in the number of IFNa+-producing pDCs (Figure 4J),
suggesting that HFD feeding promotes increased activation
and accumulation of IFNa-producing pDCs in the liver.
We next determined whether IFNa can directly induce hepatic
IR by assessing insulin intracellular signaling in Hepa 1-6 mouse
liver cells treated with recombinant IFNa. Hepatocytes treated
with IFNa showed a decreased pAkt/Akt protein ratio (Figure 4K),
indicating that the cytokine may directly induce IR in liver as a
mechanism of action during IR. Because TLR9-deficient, but
not TLR7-deficient, mice showed improved insulin signaling in
the liver (Figure 3H) and a shift in pDC phenotype (Figure 4I),
we determined the number of IFNa+ pDCs in the livers of
TLR9/mice. Consistently, the number of IFNa-producing liver
pDCs was decreased in HFD-fed TLR9/ mice compared with
HFD-fed WT controls. Collectively, these findings highlight that
changes in the inflammatory and activation statuses of immune
populations in metabolic tissues, such as macrophages in the
VAT and pDCs in the liver, are directly modulated by nucleic-
acid-targeting pathways in obesity-related IR.
Modulation of Nucleic Acid Ligands Influences Glucose
Metabolism
To directly assess the effects of TLR7 and TLR9 agonists on
glucosemetabolism, 20-week-old NCDmicewere injected intra-
peritoneally (i.p.) with either saline, specific TLR7 ligand imiqui-
mod (IMQ) (Hemmi et al., 2002), or unmethylated CpG DNA
TLR9 ligand ODN2395 (ODN) (Bauer et al., 2001). Compared
with controls, IMQ- and ODN-injected mice showed no differ-
ences in BW (Figure 5A) after 8 days of treatment. ODN, but
not IMQ, increased fasting glucose (Figure 5B), although both
TLR7 and 9 ligands worsened glucose tolerance (Figure 5C).
No changes in fasting insulin were detected (Figure 5D). To
investigate whether exogenous IMQ and ODN treatment would
influence inflammation in metabolic tissues, we examined their
macrophages and pDC populations in the VAT and liver, respec-
tively. IMQ and ODN i.p. injection increased the numbers of
CD45+ immune cells in VAT (Figure 5E), including a large in-
crease in total macrophages (Figure 5F), consistent with macro-
phage expression and responsiveness to TLR7 and TLR9 inmice. In the liver, IMQ and ODN treatments increased the total
number of pDCs (Figure 5G) and inflammatory CCR9 pDCs
(Figure 5H), although only ODN decreased the number of
CCR9+ tolerogenic pDCs (Figure 5H). These data suggest that
the proinflammatory effects of exogenous IMQ and ODN may
be manifested in part by increased numbers of macrophages
and proinflammatory pDCs in metabolic tissues.
We next determined if targeting of upstream ET-producing
pathways or downstream endosomal receptor pathways could
be exploited therapeutically in metabolic disease. Because pro-
tein arginine deiminase (PAD)4 is essential for ET formation
through histone citrullination (Li et al., 2010; Wang et al., 2009),
we treated HFD-fed mice with the PAD4 inhibitor 2-chloroaceta-
midine (2CA) (Stone et al., 2005) and then assessed their glucose
tolerance. HFD-fed mice were treated either with saline or 2CA
immediately after the initiation of HFD and up to 10 weeks of
HFD feeding. Treatment with 2CA had no effects on BW (Fig-
ure 5I), but it impaired ET formation in BM neutrophils and
monocytes (Figure S6A). Additionally, 2CA treatment reduced
ET formation in VAT macrophages, as determined by H4-Cit3
immunostaining (Figures S6B and S6C). Treatment with 2CA
improved glucose tolerance (Figure 5J, left), improved insulin
tolerance during an ITT (Figure 5J, right), and reduced fasting in-
sulin (Figure 5K), indicating that interfering with ET formation
ameliorates the effects of HFD feeding on whole-body glucose
homeostasis. Despite no changes in VAT and liver weights (Fig-
ure S6D), 2CA-treated mice showed decreased number of VAT
macrophages (Figure S6E) and pDCs in the liver (Figure S6F),
suggesting improved tissue inflammatory tone in response to
2CA treatment. Notably, HFD-fed TLR9/ mice injected with
2CA had no significant improvements in GTT (Figure 5l) and
ITT (Figure 5M), suggesting that the effects of 2CA on glucose
metabolism are partly mediated by TLR9.
We next aimed to investigate whether targeting TLR7 and
TLR9 using the immunoregulatory sequence (IRS) 954 oligonu-
cleotide also would protect HFD-fed mice from metabolic dis-
ease. IRS 954 is a dual inhibitor of TLR7 and TLR9 with previous
effectiveness in SLE (Barrat et al., 2005) and nonalcoholic stea-
tohepatitis (NASH, Garcia-Martinez et al., 2016). Despite similar
weights (Figure 5N, left), obese mice treated with IRS 954 for
3 weeks had improved glucose tolerance (Figure 5N, middle)
and a tendency for lower fasting insulin (Figure 5N, right)
compared with PBS-injected controls. Furthermore, IRS 954-
treated mice showed reduced pDCs in the liver (Figure 5O,
left), as well as increased frequency of tolerogenic CCR9+ and
reduced percentage of proinflammatory CCR9 pDCs (Fig-
ure 5O, right), suggesting improved pDC-mediated inflammation
in the liver. These data indicate that TLR7 and TLR9 are
potential targets for therapeutic agents in the prevention or
treatment of obesity-induced IR, and collectively the data high-
light nucleic acid-targeting pathways as therapeutic targets in
obesity-related IR.
DISCUSSION
We have identified a fundamental role for nucleic acid-targeting
pathways in inflammation associated with DIO. Previous reports
have shown that HFD feeding increases neutrophil recruitmentCell Reports 16, 717–730, July 19, 2016 723
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Figure 4. Macrophages in VAT and Plasmacytoid Dendritic Cells (pDCs) in the Liver Are Cellular Downstream Targets of Nucleic Acid-
Targeting Pathways
(A and B) Representative adipose tissue histology with the scale bar set at 100 mm (A) and counting of crown-like structures (CLSs) per 1003 low-power field (LPF,
B) from WT, TLR7/, and TLR9/ mice fed an HFD for 15 weeks are shown (n = 3 mice, ten LPFs per mouse).
(C–E) Absolute numbers of F4/80+ macrophages (C), expression of the macrophage activation markers CD80 and CD86 (D), and frequency of CD11c+CD206
(M1) and CD11cCD206+ (M2) macrophages (E) in the VAT (n = 5 mice per group, two experiments, *p < 0.05) of WT, TLR7/, and TLR9/mice fed an HFD for
15 weeks are shown.
(F and G) Absolute numbers of Siglec-H+PDCA-1+ pDCs in the VAT, liver, and spleen (F) and frequency of CCR9+ and CCR9 pDCs in the liver and spleen (G) of
mice fed either an NCD or HFD for 16 weeks are shown (n = 4, *p < 0.05).
(H and I) Absolute numbers of Siglec-H+PDCA-1+ pDCs in the liver and spleen (H) and frequency of CCR9+ and CCR9 pDCs in the liver (I) of WT, TLR7/, and
TLR9/ mice fed an HFD for 15 weeks are shown (n = 4, *p < 0.05).
(legend continued on next page)
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to VAT as early as 3 days upon HFD feeding (Elgazar-Carmon
et al., 2008; Talukdar et al., 2012). Here we show that neutrophil
numbers also are increased at 15 weeks after the initiation of
HFD, implicating a potential role for neutrophils in VAT inflamma-
tion during established obesity. As expected, there was also a
marked increase in macrophages in VAT during HFD (Mathis,
2013). A central role of phagocytes is their ability to use several
antimicrobial mechanisms to eliminate pathogens; however,
these same mechanisms also can contribute to tissue injury
and amplify pathologic inflammation. In our study, we show
that ET formation by phagocytes is augmented systemically
and in VAT during HFD feeding.
Increased production and reduced clearance of ETs have
been linked to inflammation and are pathogenic mediators of
autoimmune diseases, such as SLE (Garcia-Romo et al., 2011;
Hakkim et al., 2010), type 1 diabetes (Diana et al., 2013; Wang
et al., 2014b), psoriasis (Lin et al., 2011), and vasculitis (Kessen-
brock et al., 2009). Recent evidence also indicates that mice and
humans with types 1 and 2 diabetes have increased levels of cit-
rullinated histones and formation of ETs, associated with
impaired wound healing (Wong et al., 2015). ETs are networks
of fibers mainly composed of DNA, histones, and granule
proteins (Brinkmann et al., 2004). Citrullination of histones is
essential for ET formation (Neeli et al., 2008; Wang et al.,
2009). Macrophage ETs recently have been identified within
CLSs in mammary gland SAT of mice (Mohanan et al., 2013).
We show that VAT macrophages, even in non-stimulated states,
have a higher ability to release ET-like structures compared with
BM monocytes and that these ETs contribute to VAT inflamma-
tion. Given the abundance of macrophages over neutrophils in
VAT, METs are likely a dominant promoter of VAT inflammation
by ETs.
Increased formation and reduced clearance of ETs can lead to
autoantibody overproduction in SLE (Garcia-Romo et al., 2011;
Hakkim et al., 2010), andwe show that a similar phenomenon oc-
curs in DIO. Disposal of circulating nucleic acids to prevent
recognition by innate receptors and consequent inflammation
is accomplished partly by nucleases such as DNase (Martı´nez
Valle et al., 2008). The addition of exogenous DNase or MNase
restored ET degradation in serum from NCD-fed, but not from
HFD-fed, mice, suggesting that ETs are protected from general
nuclease activity during obesity. Reduced clearance of ETs likely
contributes to the increased levels of autoantibody against
conserved nuclear antigens identified in HFD mice, as observed
in SLE (Hakkim et al., 2010). In turn, these elevated levels of au-
toantibodies in HFD-fedmicemay block the access of nucleases
to ETs. Overall, this mechanism adds to existing work demon-
strating augmented production of IgG autoantibody in obesity
due to binding of macrophage-derived apoptosis inhibitor of
macrophage (AIM) to pentameric IgM complexes (Arai et al.,
2013). It was demonstrated previously that HFD-associated B
cells are pathogenic in diet-induced IR (Winer et al., 2011). The(J) Absolute numbers of IFNa+ pDCs in the liver of mice fed either an NCD or HF
(K) Total Akt and pAkt quantified by mesoscale assay in protein harvested from H
18 hr and spiked with insulin for 15 min to stimulate insulin signaling are shown (
(L) Absolute numbers of IFNa+ pDCs in the liver of WT and TLR9/ mice fed an
See also Figure S4.identity of the targeted antigens during this aberrant immune
response in HFD-fed mice remains unclear. Given the increased
levels of autoantibody against conserved nucleoproteins found
in this study, some of these antigens might be potential targets,
similar to SLE (Barrat et al., 2005). Consistently, increased IgG
autoantibody production has been identified in the VAT of
lupus-prone mice, providing one possible link between these
processes (Gabriel et al., 2012).
Activation of several TLRs, such as TLR2, TLR4, and TLR5,
has been directly implicated in the initiation of obesity-induced
inflammation. Most notably, TLR4 has been proposed to be a
critical link among the consumption of dietary fats, changes in
gut microbiota, and metabolic inflammation (Davis et al., 2008;
Saberi et al., 2009; Shi et al., 2006). During obesity-induced IR,
TLR4 can be activated by dietary factors, such as free fatty acids
(Holland et al., 2011), endogenous damage-associated molecu-
lar patterns (DAMPs) (Pal et al., 2012), and gut microbiota-
derived LPS (Cani et al., 2007; Pussinen et al., 2011). In our
study, genetic deletion and IRS 954-mediated inhibition of
TLR7 and TLR9 ameliorate the detrimental effects of HFD
feeding on glucose metabolism. Previously, TLR9-deficient
mice have shown improved IR and reduced steatohepatitis in a
model of nonalcoholic fatty liver disease (Miura et al., 2010). In
mousemodels of SLE, IRS 954 prevented the progression of dis-
ease by reducing nucleic acid autoantibodies, serum TNF-a, and
macrophage infiltration in kidney (Barrat et al., 2007; Pawar et al.,
2007). In agreement with our findings, a very recent study
showed that, compared with WT controls, diet-induced obese
TLR9-deficient mice have improved insulin tolerance, as TLR9
is involved in the recognition of DNA arising from adipocyte
death (Nishimoto et al., 2016). Therefore, targeting TLR7 and
TLR9 has promising potential therapeutic application for the
treatment of obesity-related IR.
In SLE, TLR7 and TLR9 facilitate the recognition of autoanti-
bodies against nucleic acids and activation of pDCs, which
lead to robust secretion of inflammatory cytokines, including
type I IFN (Colonna et al., 2004; Liu and Davidson, 2012). Like-
wise, self-DNA-specific antibody complexes activate TLR9 in
pancreatic pDCs, leading to the secretion of IFNa in type 1 dia-
betes (Diana et al., 2013). In our study, IFNa disrupted insulin
signaling in hepatocytes cultured in vitro, suggesting that type I
IFN responses can induce IR. However, the potential role of
IFNa in mediating IR in DIO requires further investigation
using in vivo approaches. Normally, pDCs do not respond
robustly to self-DNA, but this tolerance seems to collapse in
autoimmune diseases (Gilliet et al., 2008). We show that HFD
feeding increases the numbers of pro-inflammatory IFNa-pro-
ducing pDCs in the liver. These data are consistent with
increased loads of TLR7 and TLR9 ligands delivered to the liver
in obesity (Henao-Mejia et al., 2012), which could fuel pDC pro-
liferation and activation. Our findings also show that HFD feeding
results in a shift from tolerogenic CCR9+ to inflammatory CCR9D for 15 weeks are shown (n = 4, *p < 0.05).
epa 1-6 mouse liver cells after treatment with 100 U/ml recombinant IFNa for
triplicates, two experiments, *p < 0.05).
HFD for 15 weeks (n = 4, *p < 0.05). Error bars show mean ± SEM.
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Figure 5. Targeting Nucleic Acid-Sensing Pathways Alters Glucose Metabolism in Mice
(A–D) BWs (A), fasting glucose (B), GTT (C), and fasting insulin (D) of 20-week-old NCDmice injected daily for 8 dayswith 50 mg imiquimod (IMQ, TLR7 ligand), 2 mg
CpG ODN2395 (ODN, TLR9 ligand), or saline (CTL) are shown (n = 5, *p < 0.05).
(E and F) Absolute numbers of CD45+ immune cells (E) and F4/80+ macrophages (F) in the VAT of NCD-fed mice treated with IMQ or ODN are shown (n = 5 mice
per group, two experiments, *p < 0.05).
(G and H) Absolute numbers of Siglec-H+PDCA-1+ pDCs (G) and numbers (H) of CCR9+ and CCR9 pDCs in the liver (n = 3, *p < 0.05) of NCD-fed mice treated
with IMQ or ODN are shown.
(I–K) BWs (I), GTT (J, left), ITT (J, right), and fasting insulin (K) of HFD-fed WT mice treated every other day for 10 weeks with either 200 mg PAD inhibitor
2-chloroacetamidine (2CA) or saline (CTL) are shown (n = 5, *p < 0.05).
(L and M) GTT (L) and ITT (M) of HFD-fed TLR9/ mice treated every other day for 10 weeks with either 200 mg 2CA or saline are shown (n = 5, *p < 0.05).
(legend continued on next page)
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pDCs that may lead to prolonged inflammation and hepatocyte
damage. This inflammatory shift in liver pDCs also potentially
could contribute to the worsening state of oral tolerance seen
in obesity (Luck et al., 2015). Previous research has shown that
CCR9+, but not CCR9, pDCs potently inhibit antigen-specific
immune responses and induce Foxp3+ regulatory T cells (Ha-
deiba et al., 2008).
Our work suggests that multiple sources of nucleic acids may
contribute to glucose intolerance during DIO. First, nucleic acid
antigens arising from aberrant formation of ETs can promote
inflammation of metabolic tissues through TLR7 and TLR9. A
recent study has shown that NETs are enriched in oxidized mito-
chondrial DNA and promote a type I IFN response in a mouse
model of SLE (Lood et al., 2016). Notably, mitochondrial DNA
from hepatic origin also is found elevated in the circulation of
mice and patients with NASH, and it can promote NASH devel-
opment via activation of TLR9 (Garcia-Martinez et al., 2016).
Thus, it is conceivable that oxidized mitochondrial DNA origi-
nating from ETs and/or hepatocytes is one source of TLR9
ligands during diet-induced metabolic disease.
In our study, blocking ET release with the PAD inhibitor 2CA
improved glucose homeostasis in WT, but not in TLR9-deficient,
HFD-fed mice, implicating excessive nucleic acid release during
obesity-induced IR in a process that requires TLR9. Similar to our
findings, PAD inhibitors have been shown to reduce citrullination
and ameliorate disease in several inflammatory and autoimmune
diseases, including SLE (Knight et al., 2015), acute kidney injury
(Ham et al., 2014), rheumatoid arthritis (Willis et al., 2011), and
multiple sclerosis (Wei et al., 2013) in mice. Hence, hypercitrulli-
nation and PAD enzymes may be therapeutic targets in obesity-
related inflammation.
Second, it is possible that exogenous sources of nucleic
acids, such as CpG motifs found in bacterial DNA, can promote
obesity-induced inflammation and IR, as we have shown that a
CpG-ODN injection into lean mice worsened glucose tolerance.
Emerging evidence has linked alterations in gut microbiota dur-
ing obesity with IR (Tremaroli and Ba¨ckhed, 2012), and bacterial
DNA from intestinal origin has been shown to increase in blood
and VAT after 1 week of HFD feeding in mice (Amar et al.,
2011). Our findings suggest that, in addition to the LPS/CD14/
TLR4 axis (Cani et al., 2007, 2008), obesity-induced changes in
gutmicrobiotamay potentially promote IR via recognition of bac-
terial CpG DNA by TLR9.
Finally, a very recent study has shown that DIO is associated
with increased levels of circulating cell-free (cf) DNA, which acti-
vates macrophages in a TLR9-dependent manner (Nishimoto
et al., 2016). As cultured VAT from HFD-fed mice released
more cfDNA compared with NCD-fed controls, the authors sug-
gested that increased cfDNA owes to augmented adipocyte
death (Nishimoto et al., 2016), though other sources of nucleic
acids likely contribute to circulating cfDNA and TLR9 activation
in vivo. Additional studies are needed to pinpoint the relative
contributions of these mechanisms in obesity.(N and O) BWs (N, left), GTT (N, middle), fasting insulin (N, right), and absolute nu
CCR9 liver pDCs (O, right) inWTmice fed an HFD for 10 weeks, treated for 3 wee
IRS 954 (n = 5, *p < 0.05). Error bars show mean ± SEM.
See also Figure S6.Collectively, our data support a pathway of obesity-induced IR
in which aberrant production and handling of nucleic acid anti-
gens promote activation of immune cells in metabolic tissues,
leading to inflammatory cytokine expression. Increased loads
of systemic nuclear antigen are associated with the appearance
of autoantibodies against self-antigens in DIO, and they can
activate pDCs in the liver via TLR7/9 pathways, inducing their
expansion and production of pathogenic type I IFN. Our findings
provide evidence of roles for ET, TLR7, and TLR9 signaling in IR,
and they highlight the potential benefit of therapies that target
pathogenic nucleic acid pathways in DIO.
EXPERIMENTAL PROCEDURES
Animals
We purchased C57BL/6J, TLR7/ (B6.129S1-Tlr7tm1Flv/J, backcrossed 11
times to C57BL/6), and TLR9/ (C57BL/6J-Tlr9M7Btlr) mice from The Jackson
Laboratory. Heterozygous mice were crossed to generate WT and TLR7 or
TLR9 knockout littermates. For the HFD-induced obesitymodel, mice received
either an NCD or HFD (Research Diets, 60 kcal% fat) beginning at 6 weeks of
age. Mice were treated with the compounds IMQ/ODN (InvivoGen), 2CA
(Sigma), or IRS 954 (Dynavax). All mice were males and age-matched between
groups. All experiments were approved by the Institutional Animal Care and
Use Committee of University Health Network. For further details, see the Sup-
plemental Experimental Procedures.
Isolation of Immune Cells from Mouse Tissues
We isolated VAT, spleen, and BM immune cells as previously described (Rev-
elo et al., 2015). See the Supplemental Experimental Procedures.
Flow Cytometry
Cells were resuspended in PBS containing 2% fetal bovine serum (FBS) and
allowed to block nonspecific binding in Fc receptor blocking solution (Bio-
Legend), followed by staining with fluorophore-conjugated primary antibodies.
Detection of intracellular IFNa was performed as previously reported (Bjo¨rck
et al., 2011) after liver-derived immune cells were stimulated with or without
10 mg/ml of ODN2395 (Invivogen) for 9 hr. Data were acquired on a Fortessa
flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree
Star). See the Supplemental Experimental Procedures.
ET Quantification Assay
We measured ET release every 30 min for 6 hr using the non-cell-permeant
DNA-specific fluorescent dye Sytox Green (Molecular Probes) at a final con-
centration of 5 mM. We used a Synergy HT plate reader (BioTek Instruments)
to detect fluorescence with excitation/emission wavelengths of 530/580 nm.
Plotted fluorescence measurements taken every 30 min were used to calcu-
late areas under the curve (AUCs). See the Supplemental Experimental
Procedures.
ET Immunofluorescence Staining, SEM, and Histology
Isolated monocytes from BM and macrophages from VAT were seeded on
glass coverslips in 24-well culture plates and stimulated with 100 ng/ml of
LPS for 4 hr (Brinkmann et al., 2010). Specimens were labeled for DNA, elas-
tase, and H4Cit3 and analyzed with a Zeiss LSM700 confocal microscope.
SEM was performed by the Microscopy Imaging Lab at the University of
Toronto, as previously described (Manzenreiter et al., 2012). Histological
sections were stained with H&E and prepared for immunohistochemistry as
previously described (Revelo et al., 2015). Immunohistochemical staining of
tissue sections from human specimens was approved by the University Healthmbers of Siglec-H+PDCA-1+ liver pDCs (O, left) and frequency of CCR9+ and
ks with either scrambled oligonucleotide control (CTL) or the TLR7/9 antagonist
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Network (UHN) Research Ethics Board for Human Subjects. See the Supple-
mental Experimental Procedures.
Isolation of ET-Related Proteins and VAT Macrophage Activation
We purified NETs and METs as previously described (Urban et al., 2009). The
protein composition of these preparations was determined by MS analysis at
the SPARC BioCentre, The Hospital for Sick Children (Data S1). Purified VAT
macrophages were primed with 100 ng/ml LPS (Sigma) for 4 hr before expo-
sure to ETs, as previously reported (Kahlenberg et al., 2013). After LPS priming,
mediawere removed, cells were exposed for 2 hr to either purified ETs or RPMI
1640 at 37C, and supernatants were collected for cytokine assessment. See
the Supplemental Experimental Procedures.
Metabolic Studies
GTTs, ITTs, metabolic cage studies, and measurements of serum insulin were
performed as previously described (Revelo et al., 2015).
Auto-antigen Array
Samples were run on a custom-made auto-antigen array of 200 antigens,
and they were analyzed by hierarchical clustering (Cluster 3.0) and Statistical
Analysis of Microarray (SAM) as previously described (Price et al., 2013).
Protein ELISA and ELISPOT
ELISA immunoassays were used tomeasure supernatant concentrations of IL-
1b, TNF-a (BioLegend), anti-dsDNA, and -histone IgGs (Alpha Diagnostic In-
ternational). The frequency of spontaneous IgG-producing B cells in spleen
and VAT was determined using a mouse IgG ELISpotPLUS Kit (Mabtech) as
previously described (Winer et al., 2011). See the Supplemental Experimental
Procedures.
ANAs in Human Plasma
We obtained plasma samples from 15 normal weight (BMI 24.6 ± 0.6) and nine
overweight/obese (BMI 30.6 ± 1.6) subjects enrolled in two studies conducted
at the Toronto General Hospital (Dash et al., 2013; Xiao et al., 2014). All patients
were male and received no medication at the time of sample collection (Table
S1). Human ANAs were detected using a semiquantitative ELISA kit (Alpha
Diagnostic International). All human samples were obtained with study
approval by the Research Ethics Board for Human Subjects at the UHN. See
the Supplemental Experimental Procedures.
Degradation Assay
BM-derived neutrophils were purified frommice fed an NCD and stimulated to
release NETs. Formed NETs were then incubated with 100 U/ml DNase-1 or
10% serum from mice fed either an HFD or NCD. NETs were measured over
time using the DNA-specific fluorescent dye Sytox Green, as described in
the ET quantification assay. The amount of NET degradation by DNase-1
was considered 100% NET degradation (Hakkim et al., 2010). To determine
the presence of DNase-1 and MNase inhibitors, NETs were treated with
10% serum frommice fed either an HFD or NCD spiked with 100 U/ml of either
DNase-1 or MNase. See the Supplemental Experimental Procedures.
Acute Insulin Response and Western Blotting
We fasted mice overnight prior to i.p. injection with 1.5 units/kg insulin. VAT
and livers were harvested 15 min after acute insulin injection for quantification
of phosphorylated and total Akt (pAkt) by western blotting, as previously
described (Revelo et al., 2015). See the Supplemental Experimental
Procedures.
Murine Hepatocytes Culture
Murine liver Hepa 1-6 hepatoma cells were obtained from ATCC (mycoplasma
testing pending). We exposed the cells in duplicates for 18 hr to 100 U/ml
mouse recombinant IFNa (R&D Systems) in low-glucose medium (Gibco)
and 1% FBS. Insulin was added at 10 nM for 15 min and washed once with
ice-cold PBS, after which total protein was harvested. Before the addition of
insulin, the cells were serum starved for 2 hr. Total Akt and pAkt were
measured using a meso scale assay (Meso Scale Discovery) according to
the manufacturer’s instructions.728 Cell Reports 16, 717–730, July 19, 2016Statistical Analyses
Statistical difference between two means of continuous variables was deter-
mined by two-sided unpaired Student’s t tests using GraphPad Prism5. In
representative datasets, we conducted D’Agostino-Pearson tests to confirm
normal distributions using GraphPad Prism5. In figure legends involving mul-
tiple experiments from pooled animal tissue, the numbers of mice and biolog-
ical experiments are listed. Data are presented as means ± SEM. Statistical
significance was set at <0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, one table, and one data file and can be found with this article online
at http://dx.doi.org/10.1016/j.celrep.2016.06.024.
AUTHOR CONTRIBUTIONS
X.S.R. conceived the study, designed and performed experiments, analyzed
the data, and wrote the manuscript. M. Ghazarian, M.H.Y.C., H. Luck,
J.H.K., K.Z., S.Y.S., S. Tsai, H. Lei, J.K., C.S., and L.S. performed experiments.
C.L.L., S. Tangsombatvisit, and P.J.U. contributed the auto-autoantibody
array data. C.X. and G.F.L. provided the human plasma samples. H. Luck,
M. Ghazarian, H.T., T.J., M.W.,M. Glogauer, X.L., and E.E. reviewed themanu-
script. P.J.U. and E.E. supervised and financed parts of the project. M. Gloga-
uer financed the electronmicroscopy analyses. D.A.W. and S.W. are co-senior
authors; conceived the study; supervised the project; designed and conduct-
ed experiments; analyzed data; and led project planning, financing, andmanu-
script preparation.
ACKNOWLEDGMENTS
We thank Battista Calvieri (Microscopy Imaging Lab, University of Toronto) for
assistance with electron microscopy and Paul Taylor (SPARC BioCentre, The
Hospital for Sick Children) for assistance with protein MS analysis. We thank
the Hirano laboratory for assistance with our ELISPOT assays. This work
was supported in part by Canadian Institutes of Health Research (CIHR) grants
119414, 132562, and 142708 (D.A.W.); Canadian Diabetes Association (CDA)
grants OG-3-15-5014 and CS-5-12-3886 (D.A.W.); NIH grant HL075462 (E.E.);
and the University of Toronto Banting and Best Diabetes Centre Sun Life New
Investigator Award (D.A.W.). X.S.R. is the recipient of a CDA Postdoctoral
Fellowship.
Received: May 18, 2015
Revised: April 27, 2016
Accepted: June 3, 2016
Published: June 30, 2016
REFERENCES
Amar, J., Chabo, C., Waget, A., Klopp, P., Vachoux, C., Bermu´dez-Humara´n,
L.G., Smirnova, N., Berge´, M., Sulpice, T., Lahtinen, S., et al. (2011). Intestinal
mucosal adherence and translocation of commensal bacteria at the early
onset of type 2 diabetes: molecular mechanisms and probiotic treatment.
EMBO Mol. Med. 3, 559–572.
Arai, S., Maehara, N., Iwamura, Y., Honda, S., Nakashima, K., Kai, T., Ogishi,
M., Morita, K., Kurokawa, J., Mori, M., et al. (2013). Obesity-associated auto-
antibody production requires AIM to retain the immunoglobulin M immune
complex on follicular dendritic cells. Cell Rep. 3, 1187–1198.
Barrat, F.J., Meeker, T., Gregorio, J., Chan, J.H., Uematsu, S., Akira, S.,
Chang, B., Duramad, O., and Coffman, R.L. (2005). Nucleic acids of mamma-
lian origin can act as endogenous ligands for Toll-like receptors and may pro-
mote systemic lupus erythematosus. J. Exp. Med. 202, 1131–1139.
Barrat, F.J., Meeker, T., Chan, J.H., Guiducci, C., and Coffman, R.L. (2007).
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads
to reduction of autoantibody production and amelioration of disease symp-
toms. Eur. J. Immunol. 37, 3582–3586.
Bauer, S., Kirschning, C.J., Ha¨cker, H., Redecke, V., Hausmann, S., Akira, S.,
Wagner, H., and Lipford, G.B. (2001). Human TLR9 confers responsiveness to
bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad.
Sci. USA 98, 9237–9242.
Bjo¨rck, P., Leong, H.X., and Engleman, E.G. (2011). Plasmacytoid dendritic
cell dichotomy: identification of IFN-a producing cells as a phenotypically
and functionally distinct subset. J. Immunol. 186, 1477–1485.
Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss,
D.S., Weinrauch, Y., and Zychlinsky, A. (2004). Neutrophil extracellular traps
kill bacteria. Science 303, 1532–1535.
Brinkmann, V., Laube, B., Abu Abed, U., Goosmann, C., and Zychlinsky, A.
(2010). Neutrophil extracellular traps: how to generate and visualize them.
J. Vis. Exp. (36), 1724.
Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyr-
inck, A.M., Fava, F., Tuohy, K.M., Chabo, C., et al. (2007). Metabolic endotox-
emia initiates obesity and insulin resistance. Diabetes 56, 1761–1772.
Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M.,
and Burcelin, R. (2008). Changes in gut microbiota control metabolic endotox-
emia-induced inflammation in high-fat diet-induced obesity and diabetes in
mice. Diabetes 57, 1470–1481.
Chow, O.A., von Ko¨ckritz-Blickwede, M., Bright, A.T., Hensler, M.E., Zinkerna-
gel, A.S., Cogen, A.L., Gallo, R.L., Monestier, M., Wang, Y., Glass, C.K., and
Nizet, V. (2010). Statins enhance formation of phagocyte extracellular traps.
Cell Host Microbe 8, 445–454.
Colonna, M., Trinchieri, G., and Liu, Y.J. (2004). Plasmacytoid dendritic cells in
immunity. Nat. Immunol. 5, 1219–1226.
Dash, S., Xiao, C., Morgantini, C., Szeto, L., and Lewis, G.F. (2013). High-dose
resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein pro-
duction in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 33, 2895–
2901.
Davis, J.E., Gabler, N.K., Walker-Daniels, J., and Spurlock, M.E. (2008). Tlr-4
deficiency selectively protects against obesity induced by diets high in satu-
rated fat. Obesity (Silver Spring) 16, 1248–1255.
Demir, S., Artim-Esen, B., Sxahinkaya, Y., Pehlivan, O¨., Alpay-Kanıtez, N.,
Omma, A., Erer, B., Kamalı, S., G€ul, A., Aral, O., et al. (2016). Metabolic syn-
drome is not only a risk factor for cardiovascular diseases in systemic lupus
erythematosus but is also associated with cumulative organ damage: a
cross-sectional analysis of 311 patients. Lupus 25, 177–184.
Diana, J., Simoni, Y., Furio, L., Beaudoin, L., Agerberth, B., Barrat, F., and Le-
huen, A. (2013). Crosstalk between neutrophils, B-1a cells and plasmacytoid
dendritic cells initiates autoimmune diabetes. Nat. Med. 19, 65–73.
Elgazar-Carmon, V., Rudich, A., Hadad, N., and Levy, R. (2008). Neutrophils
transiently infiltrate intra-abdominal fat early in the course of high-fat feeding.
J. Lipid Res. 49, 1894–1903.
Gabriel, C.L., Smith, P.B., Mendez-Fernandez, Y.V., Wilhelm, A.J., Ye, A.M.,
andMajor, A.S. (2012). Autoimmune-mediated glucose intolerance in a mouse
model of systemic lupus erythematosus. Am. J. Physiol. Endocrinol. Metab.
303, E1313–E1324.
Garcia-Martinez, I., Santoro, N., Chen, Y., Hoque, R., Ouyang, X., Caprio, S.,
Shlomchik, M.J., Coffman, R.L., Candia, A., and Mehal, W.Z. (2016). Hepato-
cyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of
TLR9. J. Clin. Invest. 126, 859–864.
Garcia-Romo, G.S., Caielli, S., Vega, B., Connolly, J., Allantaz, F., Xu, Z.,
Punaro, M., Baisch, J., Guiducci, C., Coffman, R.L., et al. (2011). Netting neu-
trophils are major inducers of type I IFN production in pediatric systemic lupus
erythematosus. Sci. Transl. Med. 3, 73ra20.
Gilliet, M., Cao, W., and Liu, Y.J. (2008). Plasmacytoid dendritic cells: sensing
nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8,
594–606.
Hadeiba, H., Sato, T., Habtezion, A., Oderup, C., Pan, J., and Butcher, E.C.
(2008). CCR9 expression defines tolerogenic plasmacytoid dendritic cells
able to suppress acute graft-versus-host disease. Nat. Immunol. 9, 1253–
1260.Hakkim, A., F€urnrohr, B.G., Amann, K., Laube, B., Abed, U.A., Brinkmann, V.,
Herrmann, M., Voll, R.E., and Zychlinsky, A. (2010). Impairment of neutrophil
extracellular trap degradation is associated with lupus nephritis. Proc. Natl.
Acad. Sci. USA 107, 9813–9818.
Ham, A., Rabadi, M., Kim, M., Brown, K.M., Ma, Z., D’Agati, V., and Lee, H.T.
(2014). Peptidyl arginine deiminase-4 activation exacerbates kidney ischemia-
reperfusion injury. Am. J. Physiol. Renal Physiol. 307, F1052–F1062.
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi,
T., Tomizawa, H., Takeda, K., and Akira, S. (2002). Small anti-viral compounds
activate immune cells via the TLR7MyD88-dependent signaling pathway. Nat.
Immunol. 3, 196–200.
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W.Z., Strowig, T., Thaiss,
C.A., Kau, A.L., Eisenbarth, S.C., Jurczak, M.J., et al. (2012). Inflammasome-
mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482,
179–185.
Holland, W.L., Bikman, B.T., Wang, L.P., Yuguang, G., Sargent, K.M.,
Bulchand, S., Knotts, T.A., Shui, G., Clegg, D.J., Wenk, M.R., et al. (2011).
Lipid-induced insulin resistance mediated by the proinflammatory receptor
TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice.
J. Clin. Invest. 121, 1858–1870.
Kahlenberg, J.M., Carmona-Rivera, C., Smith, C.K., and Kaplan, M.J. (2013).
Neutrophil extracellular trap-associated protein activation of the NLRP3 in-
flammasome is enhanced in lupusmacrophages. J. Immunol. 190, 1217–1226.
Kessenbrock, K., Krumbholz, M., Scho¨nermarck, U., Back, W., Gross, W.L.,
Werb, Z., Gro¨ne, H.J., Brinkmann, V., and Jenne, D.E. (2009). Netting neutro-
phils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623–625.
Knight, J.S., Subramanian, V., O’Dell, A.A., Yalavarthi, S., Zhao, W., Smith,
C.K., Hodgin, J.B., Thompson, P.R., and Kaplan, M.J. (2015). Peptidylarginine
deiminase inhibition disrupts NET formation and protects against kidney, skin
and vascular disease in lupus-prone MRL/lpr mice. Ann. Rheum. Dis. 74,
2199–2206.
Li, P., Li, M., Lindberg, M.R., Kennett, M.J., Xiong, N., and Wang, Y. (2010).
PAD4 is essential for antibacterial innate immunity mediated by neutrophil
extracellular traps. J. Exp. Med. 207, 1853–1862.
Lin, A.M., Rubin, C.J., Khandpur, R., Wang, J.Y., Riblett, M., Yalavarthi, S., Vil-
lanueva, E.C., Shah, P., Kaplan, M.J., and Bruce, A.T. (2011). Mast cells and
neutrophils release IL-17 through extracellular trap formation in psoriasis.
J. Immunol. 187, 490–500.
Liu, Z., and Davidson, A. (2012). Taming lupus-a new understanding of patho-
genesis is leading to clinical advances. Nat. Med. 18, 871–882.
Liu, P., Wu, X., Liao, C., Liu, X., Du, J., Shi, H., Wang, X., Bai, X., Peng, P., Yu,
L., et al. (2014). Escherichia coli and Candida albicans induced macrophage
extracellular trap-like structures with limited microbicidal activity. PLoS ONE
9, e90042.
Lood, C., Blanco, L.P., Purmalek, M.M., Carmona-Rivera, C., De Ravin, S.S.,
Smith, C.K., Malech, H.L., Ledbetter, J.A., Elkon, K.B., and Kaplan, M.J.
(2016). Neutrophil extracellular traps enriched in oxidized mitochondrial DNA
are interferogenic and contribute to lupus-like disease. Nat. Med. 22, 146–153.
Luck, H., Tsai, S., Chung, J., Clemente-Casares, X., Ghazarian, M., Revelo,
X.S., Lei, H., Luk, C.T., Shi, S.Y., Surendra, A., et al. (2015). Regulation of
obesity-related insulin resistance with gut anti-inflammatory agents. Cell
Metab. 21, 527–542.
Manzenreiter, R., Kienberger, F., Marcos, V., Schilcher, K., Krautgartner, W.D.,
Obermayer, A., Huml, M., Stoiber, W., Hector, A., Griese, M., et al. (2012). Ul-
trastructural characterization of cystic fibrosis sputum using atomic force and
scanning electron microscopy. J. Cyst. Fibros. 11, 84–92.
Martin, D.A., and Elkon, K.B. (2005). Autoantibodies make a U-turn: the toll hy-
pothesis for autoantibody specificity. J. Exp. Med. 202, 1465–1469.
Martı´nez Valle, F., Balada, E., Ordi-Ros, J., and Vilardell-Tarres, M. (2008).
DNase 1 and systemic lupus erythematosus. Autoimmun. Rev. 7, 359–363.
Mathis, D. (2013). Immunological goings-on in visceral adipose tissue. Cell
Metab. 17, 851–859.Cell Reports 16, 717–730, July 19, 2016 729
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olef-
sky, J.M., Brenner, D.A., and Seki, E. (2010). Toll-like receptor 9 promotes
steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology
139, 323–334.
Mohanan, S., Horibata, S., McElwee, J.L., Dannenberg, A.J., and Coonrod,
S.A. (2013). Identification of macrophage extracellular trap-like structures in
mammary gland adipose tissue: a preliminary study. Front. Immunol. 4, 67.
Neeli, I., Khan, S.N., and Radic, M. (2008). Histone deimination as a response
to inflammatory stimuli in neutrophils. J. Immunol. 180, 1895–1902.
Nishimoto, S., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Murata, C.,
Kim-Kaneyama, J.R., Sato, F., Bando, M., Yagi, S., et al. (2016). Obesity-
induced DNA released from adipocytes stimulates chronic adipose tissue
inflammation and insulin resistance. Sci. Adv. 2, e1501332.
Osborn, O., and Olefsky, J.M. (2012). The cellular and signaling networks link-
ing the immune system and metabolism in disease. Nat. Med. 18, 363–374.
Pal, D., Dasgupta, S., Kundu, R., Maitra, S., Das, G., Mukhopadhyay, S., Ray,
S., Majumdar, S.S., and Bhattacharya, S. (2012). Fetuin-A acts as an endoge-
nous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 18,
1279–1285.
Parker, B., and Bruce, I.N. (2010). The metabolic syndrome in systemic lupus
erythematosus. Rheum. Dis. Clin. North Am. 36, 81–97, viii.
Parker, B., Urowitz, M.B., Gladman, D.D., Lunt, M., Donn, R., Bae, S.C., San-
chez-Guerrero, J., Romero-Diaz, J., Gordon, C., Wallace, D.J., et al. (2015).
Impact of early disease factors on metabolic syndrome in systemic lupus ery-
thematosus: data from an international inception cohort. Ann. Rheum. Dis. 74,
1530–1536.
Pawar, R.D., Ramanjaneyulu, A., Kulkarni, O.P., Lech, M., Segerer, S., and An-
ders, H.J. (2007). Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9
attenuates glomerulonephritis and lung injury in experimental lupus. J. Am.
Soc. Nephrol. 18, 1721–1731.
Price, J.V., Haddon, D.J., Kemmer, D., Delepine, G., Mandelbaum, G., Jarrell,
J.A., Gupta, R., Balboni, I., Chakravarty, E.F., Sokolove, J., et al. (2013). Pro-
tein microarray analysis reveals BAFF-binding autoantibodies in systemic
lupus erythematosus. J. Clin. Invest. 123, 5135–5145.
Pussinen, P.J., Havulinna, A.S., Lehto, M., Sundvall, J., and Salomaa, V.
(2011). Endotoxemia is associated with an increased risk of incident diabetes.
Diabetes Care 34, 392–397.
Revelo, X.S., Tsai, S., Lei, H., Luck, H., Ghazarian, M., Tsui, H., Shi, S.Y.,
Schroer, S., Luk, C.T., Lin, G.H., et al. (2015). Perforin is a novel immune regu-
lator of obesity-related insulin resistance. Diabetes 64, 90–103.
Saberi, M., Woods, N.B., de Luca, C., Schenk, S., Lu, J.C., Bandyopadhyay,
G., Verma, I.M., and Olefsky, J.M. (2009). Hematopoietic cell-specific deletion
of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance
in high-fat-fed mice. Cell Metab. 10, 419–429.
Savarese, E., Chae, O.W., Trowitzsch, S., Weber, G., Kastner, B., Akira, S.,
Wagner, H., Schmid, R.M., Bauer, S., and Krug, A. (2006). U1 small nuclear
ribonucleoprotein immune complexes induce type I interferon in plasmacytoid
dendritic cells through TLR7. Blood 107, 3229–3234.
Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. (2006).
TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin.
Invest. 116, 3015–3025.730 Cell Reports 16, 717–730, July 19, 2016Stone, E.M., Schaller, T.H., Bianchi, H., Person, M.D., and Fast, W. (2005).
Inactivation of two diverse enzymes in the amidinotransferase superfamily
by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase.
Biochemistry 44, 13744–13752.
Talukdar, S., Oh, Y., Bandyopadhyay, G., Li, D., Xu, J., McNelis, J., Lu, M., Li,
P., Yan, Q., Zhu, Y., et al. (2012). Neutrophils mediate insulin resistance inmice
fed a high-fat diet through secreted elastase. Nat. Med. 18, 1407–1412.
Tillack, K., Breiden, P., Martin, R., and Sospedra, M. (2012). T lymphocyte
priming by neutrophil extracellular traps links innate and adaptive immune re-
sponses. J. Immunol. 188, 3150–3159.
Tremaroli, V., and Ba¨ckhed, F. (2012). Functional interactions between the gut
microbiota and host metabolism. Nature 489, 242–249.
Urban, C.F., Ermert, D., Schmid, M., Abu-Abed, U., Goosmann, C., Nacken,
W., Brinkmann, V., Jungblut, P.R., and Zychlinsky, A. (2009). Neutrophil extra-
cellular traps contain calprotectin, a cytosolic protein complex involved in host
defense against Candida albicans. PLoS Pathog. 5, e1000639.
Wang, Y., Li, M., Stadler, S., Correll, S., Li, P., Wang, D., Hayama, R., Leonelli,
L., Han, H., Grigoryev, S.A., et al. (2009). Histone hypercitrullination mediates
chromatin decondensation and neutrophil extracellular trap formation. J. Cell
Biol. 184, 205–213.
Wang, Q., Xie, Z., Zhang, W., Zhou, J., Wu, Y., Zhang, M., Zhu, H., and Zou,
M.H. (2014a). Myeloperoxidase deletion prevents high-fat diet-induced
obesity and insulin resistance. Diabetes 63, 4172–4185.
Wang, Y., Xiao, Y., Zhong, L., Ye, D., Zhang, J., Tu, Y., Bornstein, S.R., Zhou,
Z., Lam, K.S., and Xu, A. (2014b). Increased neutrophil elastase and proteinase
3 and augmented NETosis are closely associated with b-cell autoimmunity in
patients with type 1 diabetes. Diabetes 63, 4239–4248.
Webster, S.J., Daigneault, M., Bewley, M.A., Preston, J.A., Marriott, H.M.,
Walmsley, S.R., Read, R.C., Whyte, M.K., and Dockrell, D.H. (2010). Distinct
cell death programs in monocytes regulate innate responses following chal-
lenge with common causes of invasive bacterial disease. J. Immunol. 185,
2968–2979.
Wei, L., Wasilewski, E., Chakka, S.K., Bello, A.M., Moscarello, M.A., and Kotra,
L.P. (2013). Novel inhibitors of protein arginine deiminasewith potential activity
in multiple sclerosis animal model. J. Med. Chem. 56, 1715–1722.
Willis, V.C., Gizinski, A.M., Banda, N.K., Causey, C.P., Knuckley, B., Cordova,
K.N., Luo, Y., Levitt, B., Glogowska, M., Chandra, P., et al. (2011). N-a-ben-
zoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deimi-
nase inhibitor, reduces the severity of murine collagen-induced arthritis.
J. Immunol. 186, 4396–4404.
Winer, D.A., Winer, S., Shen, L., Wadia, P.P., Yantha, J., Paltser, G., Tsui, H.,
Wu, P., Davidson, M.G., Alonso, M.N., et al. (2011). B cells promote insulin
resistance through modulation of T cells and production of pathogenic IgG an-
tibodies. Nat. Med. 17, 610–617.
Wong, S.L., Demers, M., Martinod, K., Gallant, M., Wang, Y., Goldfine, A.B.,
Kahn, C.R., and Wagner, D.D. (2015). Diabetes primes neutrophils to undergo
NETosis, which impairs wound healing. Nat. Med. 21, 815–819.
Xiao, C., Dash, S., Morgantini, C., Patterson, B.W., and Lewis, G.F. (2014). Si-
tagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secre-
tion in healthy humans. Diabetes 63, 2394–2401.
